secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001558370-23-019795
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path completes first dose cohort of BP1002 Phase 1/1b trial in AML; no dose-limiting toxicities
--------------------------------------------------------------------------------

- First cohort (20 mg/m2) completed with no dose-limiting toxicities in 3 evaluable refractory/relapsed AML patients.
- BP1002 uses RNAi to limit Bcl-2 protein production, offering potential treatment for venetoclax-resistant patients.
- Treatment cycle: two doses per week for 4 weeks (8 doses over 28 days).
- Phase 1b portion will assess BP1002 in combination with decitabine after monotherapy cohorts.
- National PI is Dr. Gail Roboz, director of Clinical and Translational Leukemia Program at Weill Cornell.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023019795/0001558370-23-019795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023019795/bpth-20231214x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer